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Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a genetically transmitted disease. However, the ge-
netics are more complex than in other inherited conditions wherein a single gene abnormal mutation may be
causative. In ARVC, 5 causative desmosomal genes have been identified, but because only 30% to 50% of pa-
tients with ARVC have 1 of these gene abnormalities, it is assumed that there are other genes not yet identified.
Frequently, patients with ARVC have 1 genetic defect in the same gene (compound heterozygosity) or in a sec-
ond complementary gene (digenic heterozygosity). In addition, a family member may have an ARVC gene defect
and have development of the disease or have no or minimal manifestations of the disease. Clinical genetic test-
ing is commercially available. It is beneficial for first-degree family members of a person with ARVC to have ge-
netic testing but only if there is a known genetic abnormality in the affected person. If the affected family mem-
ber (proband) with ARVC does not have a genetic defect identified, then it will not be identified in the family
member. Genetic counseling is strongly advised for family members of the proband. (J Am Coll Cardiol 2013;
61:1945–8) © 2013 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2013.01.073t
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cArrhythmogenic right ventricular cardiomyopathy (ARVC)
is caused by abnormalities in heart cells that connect to each
other through cell-cell contacts known as the intercalated
disc, with abnormalities in a portion of the intercalated disc
called the desmosome. Typically, this abnormality causes a
disruption of the normal structure and function of specific
desmosomal proteins, leading to “pulling apart” of these
cell-cell contacts. In ARVC, the muscle cells affected
initially are primarily in the right ventricle, although the left
ventricle may be involved later in the course of ARVC or
occasionally be an early or predominant site of the disease
(1). ARVC is inherited as an autosomal dominant trait,
meaning that the risk of a family member inheriting an
abnormal gene is 50% for all offspring of the genetically
affected proband, whether male or female. Only 30% to 50%
of patients with ARVC have an abnormal gene that has
been identified as causative of the disease (Table 1) (2,3).
his percent is variable and ranges from 26% to 58%, with
he higher percent in patients with clinical familial disease
4,5). Other ARVC patients may have abnormal genes, but
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2012, accepted January 8, 2013.hey have not yet been found. Mutations may be inherited
rom a parent or may be the result of a new mutation.
pproximately 20% to 30% of patients with ARVC have a
amily history of ARVC or of sudden death. Once a person
as a mutation, whether inherited or a new mutation, there
s a 50% chance that the mutation will be passed on to the
hildren of the person with the mutation.
Desmosomes are present not only in the cardiac muscle
ut also in the skin and hair follicles. If both parents have
he same genetic desmosomal abnormalities, then the chil-
ren will all inherit the desmosomal defect that may involve
he skin as well as the heart. One of these conditions is
nown as Naxos disease and involves mutations in genes
ncoding the cell adhesion proteins plakoglobin and des-
oplakin (6). The affected persons have thickened palms
nd soles of their feet as well as the cardiac manifestation of
ight ventricle cardiomyopathy. Another variety of this type
f inheritance has been reported from Ecuador and is called
arvajal syndrome in which the cardiac involvement pri-
arily involves the left ventricle.
A person who has a gene mutation for ARVC inherits the
isk of having the disease but may or may not develop signs
nd symptoms of the disease. Other factors such as the
resence of an additional gene abnormality or 2 abnormal-
ties within the same class of genes such as plakophilin-2,
xposure to certain viruses, athletic lifestyle, and so forth,
an determine whether the person is clinically affected with
RVC. This is an area of active research.
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Genetic testing can be useful to
determine whether a person who
is suspected of having ARVC
has the disease. It is also useful
to identify relatives who do not
have signs or symptoms of ARVC but have the gene defect.
Mutation-specific testing is recommended when a genetic
diagnosis of ARVC is made in the family member (pro-
band) to determine the possible risk in close relatives (7).
The test can be helpful in several ways. If a person has a
gene thought to be causal for ARVC and has first-degree
relatives (brothers, sisters, children), the finding of the same
gene defect in a family member indicates that they are at risk
and should be evaluated at intervals to determine whether
the disease becomes evident. If an abnormal gene is present
in the proband and not in family members, it is unlikely that
the family members have the disease or will have the disease
based on that genetic abnormality. However, the proband
may have a second gene defect not identified that could
confound this assumption. If no genetic abnormalities are
found in the proband, this is not unequivocal evidence that
the disease is not caused by a gene mutation because fewer
than half of the genetic causes of ARVC are currently
known. When the affected proband has the causative gene
definitively identified and family members are found to carry
the same gene defect, periodic heart screening is required
whether or not they have signs or symptoms of the disease.
If genetic testing is not performed in relatives, there may be
a psychological impact on these persons who must reconcile
themselves to lifelong screenings without the prospect of a
definite diagnosis. The other alternative would be to pre-
sume that they do not have the disease and accept the
possibility that a minority of them and/or their children
could experience a tragic cardiac event.
There are several observations that complicate the inter-
pretation of genetic testing for ARVC. In general, the
ARVC genes cause mutations in desmosomal proteins that
disturb cell-cell contacts. The gene that has most commonly
been reported to cause clinical signs or symptoms of ARVC
is called plakophilin-2. However, this genetic abnormality
may require a second mutation in that gene or in another
desmosomal gene to cause signs or symptoms of ARVC.
The interpretation of an “abnormal gene” for ARVC must
also take into consideration the probability that the gene
that is identified as abnormal is indeed causative. A truly
abnormal desmosomal gene identified as causing the disease
is not supposed to be found in 1 in 400 persons who do
not have the disease. Yet it has been reported that 1 in every
200 healthy Finnish people have a desmosomal mutation
that may predispose to ARVC (8). Other studies have
shown that in persons of Asian descent, as many as 6% of
healthy controls have an “abnormal” plakophilin-2 gene
(5,9). The genetic test laboratory generally provides infor-
Abbreviation
and Acronym
ARVC  arrhythmogenic
right ventricular
cardiomyopathymation relating to the specificity of the suspected geneticabnormality but because of the complex genetics of ARVC,
even these reports can be difficult to interpret. Genetic
counseling is important to help clarify the results.
An additional problem in interpreting tests results is that
as many as 48% of people who clearly have the disease may
have at least 2 different genetic mutations (4,10–13). In
general, persons who have 2 mutations usually have more
severe signs and symptoms of ARVC. Because not all the
genes associated with ARVC have been identified, consider
the following scenario: A person has clinical evidence of ARVC,
and a “pathological gene” (e.g., plakophilin-2) is identified. That
person may have an additional gene defect that has not been
recognized. Suppose that proband’s family members are
tested genetically and do not have the plakophilin-2 gene,
and they assume that they do not have the possibility of
developing ARVC. However, those persons actually do have
a chance of having an unknown gene that is present in the
affected proband (together with the plakophilin-2 mutation)
that actually causes the disease. If this unidentified gene is
transmitted from the proband with ARVC who has the 2
gene defects to the family members, then the disease may
develop in them even though the plakophilin-2 mutation is
not transmitted (14). That is important because the family
members who have the otherwise unknown gene defect are
clearly at risk but may have been told otherwise. Therefore,
the family members who are “gene negative” should prob-
ably have intermittent examinations for the disease even if
they, too, test gene negative.
Periodic examinations of persons who test positive for an
ARVC genetic abnormality but do not have evidence of the
disease should be performed as follows: Cardiac evaluation
should begin at 10 to 12 years of age because the disease
rarely expresses itself before then. Suggested tests include an
electrocardiogram, signal-averaged electrocardiogram, echo-
cardiogram, possibly a magnetic resonance imaging examina-
tion, and a Holter monitor. It is suggested that evaluation be
done every 2 years between the ages of 10 and 20 years, and
every 5 years after 20 years of age. Screening can be stopped
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Table 1
Desmosomal Genetic Mutations and Distribution
of Desmosomal Genetic Abnormalities in 2 Large
Series of Patients With Arrhythmogenic Right
Ventricular Cardiomyopathy
Desmosomal Genetic Mutations Series A (4) Series B (5)
Total number of patients 198 175
Patients with positive desmosomal
genetic abnormalities
52 (26.7%) 102 (58%)
Distribution of Desmosomal Genetic Abnormalities (n  52)* (n  102)†
Plakophilin-2 73.0% 78.4%
Desmoglein-2 9.6% 13.5%
Desmoscollin-2 5.8% 3.6%
Desmoplakin 7.7% 2.7%
Junctional plakoglobin 3.8% 0.9%
*Of patients with plakophilin-2 genetic variants, 25 of 38 (65.7%) were found to have a second
plakophilin-2 abnormality or a second abnormal desmosomal gene. †12 of 102 patients (11.8%)
with genetic variants had 2 or more abnormal desmosomal genes.
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presents after that.
A person with ARVC who clearly has the disease may not
personally benefit from genetic testing because the presence
or absence of a gene defect would not alter the treatment or
prognosis in that person because a definitive clinical predic-
tion cannot be based on the genetics at this time. It is not
known whether the minority of patients with 1 genetic
abnormality for ARVC should have an implantable
cardioverter-defibrillator inserted for less than the usual
indications because they may be more likely to develop
severe disease (15). Uncommonly, other diseases such as
sarcoidosis can mimic signs and symptoms of ARVC.
Therefore, positive gene identification for ARVC could be
helpful to exclude the likelihood of the person having a
different heart disease.
Clinical Genetic Testing
Clinical genetic testing for ARVC genetic abnormalities is
available in the United States and should be performed in
certified diagnostic laboratories (see Addendum). It usually
requires submitting a small blood sample. Currently, there
are 5 abnormal desmosomal genes that have been identified
and are being analyzed as part of a panel for routine genetic
testing.
Costs for Genetic Testing
Although laboratory fees for genetic testing vary, most
genetic testing laboratories accept commercial insurance. A
genetic test for ARVC can cost as much as $5,400. Some
laboratories may not accept Medicare or Medicaid. Also, a
credit card guarantee may be required for some insurance
plans such as Blue Cross and Blue Shield, and so forth.
Some laboratories have special arrangements, and a genetic
counselor should be engaged in the discussion.
After the signed physician request form has been re-
ceived, some genetic testing laboratories will offer to contact
the patient’s insurance company to determine the out-of-
pocket expense after the copay and deductible. If genetic
testing is being considered, it may be advisable to seek
authorization from one’s insurance company to determine
whether subsequent diagnostic tests and treatment may be
covered after genetic testing.
Genetic Testing in Unusual Circumstances
Genetic testing at autopsy. Genetic testing can confirm
he cause of sudden death, particularly in a young person in
hom ARVC is suspected at autopsy but the diagnosis is
ot definitive (15). Blood samples from that person should
e tested for ARVC. If the genetic test is positive, family
creening is strongly advised. It should be mentioned that
enetic testing for other possible causes of sudden death due
o inherited diseases such as the long QT syndrome shouldalso be performed if there is no obvious cause for sudden
death.
Prenatal diagnosis. The decision of persons with ARVC
to conceive a child is difficult and should be made on a
case-by-case basis (16). Other options to be considered are
adoption, artificial insemination using donated mature eggs
or sperm, and pre-implantation genetic diagnosis. Another
option is the use of in vitro fertilization to conceive embryos
that can be tested for the family mutation before being
implanted in the mother. This procedure is restricted to
severe and untreatable diseases.
Some couples may request prenatal diagnosis through
amniocentesis at the beginning of the pregnancy to deter-
mine the genetic status of the fetus and to consider
terminating the pregnancy if the gene mutation is present.
Ethical and legal issues apply in these situations.
Benefits of Using a Genetic Counselor
Genetic counseling is recommended for all patients with a
genetically transmitted heart disease. A genetic counselor is
a health-care professional who is specially trained in medical
genetics and patient counseling. They assist both patients
and physicians in the genetic testing process. Some genetic
counseling services are offered to patients by telephone.
Genetic counseling sessions usually consist of a review of the
patient’s diagnosis, obtaining a detailed family history,
discussion of test results, review of cost and insurance issues,
coordination of the testing process, and discussion of test
results in family members.
Genetic counselors are trained in both the technical and
psychological aspects of genetic testing. Most patients
diagnosed with ARVC want to understand why their
condition developed and their prognosis. They are also
concerned about their family members having the disease.
Genetic counselors can also help with questions about
insurance and assist in completion of paperwork associated
with genetic testing. Some companies provide free genetic
counseling services to their patients or their physicians.
For more information regarding genetic counseling
and/or referrals for a genetic counselor in your area, consult
your physician, or contact the National Society of Genetic
Counselors.
Summary
At present, the interpretation of genetic tests for ARVC is
not an exact science and is more complex than for other
heart disorders caused by only a single gene and for which
most patients will have an abnormal gene identified. The
clinical application of genetic testing for ARVC is that it
can be helpful to understand the cause of this disease, to
identify family members who are at risk of this condition,
for family planning, and for limited prognostic information.
The deoxyribonucleic acid variants of undetermined signif-
icance can result in uncertainty, and incorrect explanations
can cause serious errors in medical practice. Genetic testing
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with caution and with the support of services that assist in
the interpretation of results.
Addendum
These commercial genetic laboratories perform genetic
testing for ARVC/D:
GeneDX, 207 Perry Parkway, Gaithersburg, Maryland 20877
Phone: (301) 519-2100
www.genedx.com
Transgenomic (formerly PGx Health), 5 Science Park,
New Haven, Connecticut 06511
Phone: (877) 274-9432; Fax: (203) 786-3418
www.transgenomic.com
Correlagen Diagnostics, Inc., 307 Waverly Oaks Road,
Suite 101, Waltham, Massachusetts 02453
Phone: (781) 647-0604; Fax: (781) 647-0626
www.correlagen.com
AMBRY Genetics, 15 Argonaut, Aliso Viejo, California 92856
Phone: (949) 900-5500; Fax: (949) 900-5501
www.ambrygen.com
PGx Health, Familion Genetic Tests, Five Science Park,
New Haven, Connecticut 06511
Phone: (877) 274-9432
www.pgxhealth.com
LabCorp, 358 South Main Street,
Burlington, North Carolina 27215
Phone: (336) 584-5171
www.labcorp.com
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